MDMXF (Medmix AG) Growth Rank: 4 (As of Aug. 20, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDMXF Medmix AG MDMXF
67 GF Score
Price $17.40
GF Value $17.10
! 6 Warning Signs
View Full Analysis

What is Medmix AG Growth Rank?

Medmix AG MDMXF 67 Growth Rank is 4 as of Aug. 20, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates MDMXF with a GF Score™ of 67/100 and a GF Value™ of $17.10. The stock has 6 warning signs investors should review.

Medmix AG has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

MDMXF vs GEV, ETN, PH: Growth Rank Comparison

For the Specialty Industrial Machinery subindustry, Medmix AG's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medmix AG Growth Rank vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Medmix AG's Growth Rank distribution charts can be found below:

* The bar in red indicates where Medmix AG's Growth Rank falls into.


MDMXF
67GF Score
Medmix AG MDMXF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Medmix AG (MDMXF) has a Growth Rank of 4 as of Aug. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medmix AG and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Medmix AG's Growth Rank has ranged from 2.00 to 8.00.
Is Medmix AG's Growth Rank too high?
Medmix AG's current Growth Rank of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. Overall, Medmix AG has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Growth Rank compare to GEV and ETN?
Medmix AG's Growth Rank of 4 can be compared against companies in the Industrial Products industry. Historically, Medmix AG's own Growth Rank has ranged from 2.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for an Industrial Products company?
A good Growth Rank depends on the Industrial Products industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Medmix AG and its competitors. Medmix AG's current Growth Rank is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current Growth Rank of 4. The stock's GF Value™ is $17.10, compared to a current price of $17.40 — trading 1.8% above its estimated fair value. The current Growth Rank is 4, which is 33% below median its 10-year median of 6.00. Medmix AG's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Medmix AG (MDMXF), the current Growth Rank is 4 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medmix AG (MDMXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medmix AG stock appears to be overvalued. The current stock price of $17.40 is trading 1.8% above its estimated GF Value™ of $17.10.

Key valuation signals for MDMXF:

  • Growth Rank: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: $17.10 vs. price of $17.40 (1.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medmix AG Business Description

Other Exchanges MEDXz:UKMEDX:Switzerland
Address Neuhofstrasse 20, Baar, CHE, 6340
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
67GF Score

Get the complete analysis for MDMXF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.40
Price
$17.10
GF Value